Please assess the completion status of the following clinical trial:

Trial Title: Gene Therapy for Blindness Caused by Choroideremia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study,~* Male aged 18 years or above,~* Diagnosed with choroideraemia and in good health,~* Active disease with SLO changes visible within the macula region,~* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study,~* Vision at least 6/60 or better in the study eye.~Exclusion Criteria:~* Female and child participants (under the age of 18),~* Men unwilling to use barrier contraception methods, if relevant,~* Previous history of retinal surgery or ocular inflammatory disease (uveitis),~* Grossly asymmetrical disease or other ocular morbidity which might confound use of the fellow eye as a long-term control,~* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study,~* Participants who have participated in another research study involving an investigational product in the previous 12 weeks.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose 1 (Type: EXPERIMENTAL): Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
- Dose 2 (Type: EXPERIMENTAL): Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).